Anti-Cancer Agents in Medicinal Chemistry

(Formerly 'Current Medicinal Chemistry - Anti-Cancer Agents')

ISSN: 1871-5206

Anti-Cancer Agents in Medicinal Chemistry
Volume 6, Number 4, July 2006

Contents


Hypoxia: Targeting the Tumour Pp. 281-286
R.G. Boyle and S. Travers
[Abstract]


From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy Pp. 287-301
B. Gatto and M. Cavalli
[Abstract]


Syntheses, Molecular Targets and Antitumor Activities of Novel Triptycene Bisquinones and 1,4-Anthracenedione Analogs Pp. 303-318
D.H. Hua, K. Lou, S.K. Battina, H. Zhao, E.M. Perchellet, Y. Wang and J.-P.H. Perchellet
[Abstract]


Potential of Cyclopenta[b]Benzofurans from Aglaia Species in Cancer Chemotherapy Pp. 319-345
S. Kim, A.A. Salim, S.M. Swanson and A.D. Kinghorn
[Abstract]


Evaluation of Natural and Synthetic Compounds from East Asiatic Folk Medicinal Plants on the Mediation of Cancer Pp. 347-365
T.-H. Tseng and Y.-J. Lee
[Abstract]


Cytotoxic Molecules from Natural Sources: Tapping the Brazilian Biodiversity Pp. 367-375
I.B. Suffredini, A.D. Varella and R.N. Younes
[Abstract]


Chk1 Inhibitors for Novel Cancer Treatment Pp. 377-388
Z.-F. Tao and N.-H. Lin
[Abstract]




Abstracts

[Back to top]
Hypoxia: Targeting the Tumour
R.G. Boyle and S. Travers

Solid tumours contain regions of very low oxygen concentrations that are said to be hypoxic. Hypoxia is a natural phenotype of solid tumours resulting from an imperfect vascular network. There are a number of consequences associated with tumour hypoxia including: resistance to ionising radiation, resistance to chemotherapy and the magnification of mutated p53. In addition tissue hypoxia has been regarded as a key factor for tumour aggressiveness and metastasis by activation of signal transduction pathways and gene regulatory mechanisms.

It is clear that hypoxia in solid tumours promotes a strong oncogenic phenotype and is a phenomenon that occurs in all solid tumours. As such this provides a significant target for drug discovery particularly for tumour-targeting agents. A range of chemical classes (N-oxides, quinones, nitro-aromatics) have been explored as bioreductive agents that target tumour hypoxia. The most advanced agent, tirapazamine, is in phase III clinical trials in combination with cis-platin. The aim of this review is to give a brief overview of the current molecules and strategies being explored for targeting tumour hypoxia.


[Back to top]
From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy
B. Gatto and M. Cavalli

Cancer cells, by releasing pro-angiogenic factors, stimulate the growth of the thick capillary net necessary for the nourishment of the tumor mass. The battle to defeat cancer uses today different approaches based on the inhibition of pathological angiogenesis: several compounds, either synthetic or biotech, aimed at this complex process, are under development.

Vascular endothelial growth factor (VEGF) is considered the main target for an anti-cancer therapy based on angiogenesis inhibition; the goal is to block the interaction between this cytokine and its receptors in order to stop the intracellular signaling pathways leading to endothelium remodeling. FDA recently approved two drugs specifically aimed at VEGF, bevacizumab, a humanized monoclonal antibody, and pegaptinib, a pegylated aptamer with application in ophthalmic pathologies.

These two approvals validate anti-VEGF therapy for clinical use, and show how biotech companies are investing on angiogenesis using different approaches, i.e. exploiting protein drugs and oligonucleotide-based therapeutics. Monoclonal antibodies, as well as other high molecular weight products like cytokine-traps, aptamers and short interfering RNA (siRNA), are designed to target VEGF and its receptors. Their design, production and clinical advancement in cancer and other pathological conditions linked to angiogenesis will be specifically addressed in this review.


[Back to top]
Syntheses, Molecular Targets and Antitumor Activities of Novel Triptycene Bisquinones and 1,4-Anthracenedione Analogs
D.H. Hua, K. Lou, S.K. Battina, H. Zhao, E.M. Perchellet, Y. Wang and J.-P.H. Perchellet

Novel substituted triptycene bisquinones and 1, 4-anthracenediones were synthesized and screened for their anti-cancer activities. A number of analogs were synthesized utilizing various synthetic transformations and found to elicit interesting antitumor effects. Analogs included water-soluble pro-drugs and ammonium salts. These potent antitumor drugs are DNA topoisomerase inhibitors that induce DNA strand breaks, inhibit DNA, RNA and protein syntheses and reduce tumor cell proliferation in the nanomolar range in vitro. They induce cytochrome c release, caspase-9, -3 and -8 activities, poly(ADP)-ribose polymerase-1 (PARP) cleavage, and internucleosomal DNA fragmentation by a mechanism which involves caspase-2 activation but not Fas signaling. Moreover, these drugs remain effective in multidrug-resistant tumor cells and have the advantage of blocking nucleoside transport and inducing a rapid loss of mitochondrial transmembrane potential. Based on their effects in tumor cells and isolated mitochondria, it is hypothesized that these drugs might, directly and indirectly, target components of the permeability transition pore to induce mitochondrial permeability transition and the release of proapoptotic factors. This review provides a summary of synthetic efforts and mechanistic endeavor.


[Back to top]
Potential of Cyclopenta[b]Benzofurans from Aglaia Species in Cancer Chemotherapy
S. Kim, A.A. Salim, S.M. Swanson and A.D. Kinghorn

During the past few years, a group of cyclopenta[b]benzofurans from the plant genus Aglaia has received broad scientific attention as interesting natural product lead compounds with potential anticancer and insecticidal activities. Since the first cyclopenta[b]benzofuran derivative, rocaglamide, from Aglaia elliptifolia, was found to exhibit antileukemic activity in a murine in vivo model, the genus Aglaia has been subjected to further investigation. Over 40 cyclopenta[b]benzofurans have been tested against different human cancer cell lines, and the cumulative results provide some important clues as to how to improve their activity through modification of their chemical structures. The semisynthesis and total synthesis of the cyclopenta[b]benzofurans have been conducted. Although the ultimate molecular target(s) responsible for their antiproliferative activity has not yet been identified, studies on their cellular mechanism of action have demonstrated that some of these compounds inhibit TNF-α or PMA-induced NF-κB activity in T-lymphocytes and induce apoptosis in different human cancer cell lines. Based on the published data thus far, cyclopenta[b]benzofurans offer excellent potential as therapeutic agent candidates in cancer chemotherapy, even if much work still remains to be done for their further development.


[Back to top]
Evaluation of Natural and Synthetic Compounds from East Asiatic Folk Medicinal Plants on the Mediation of Cancer
T.-H. Tseng and Y.-J. Lee

In this review are presented various lead compounds bearing a polyphenolic moiety and their biological targets. The relevance of these targets to develop the desired compounds as potential anti-cancer agents is discussed. For instance, caffeic acid phenethyl ester (CAPE) has preliminary been studied in our group to hold various biochemical responses. When C6 glioma cells were grown as xenografts in nude mice, treatment with CAPE (1-10 mg/kg; ip) induced a significant dose dependent decrease in tumor growth by evaluating tumor volume and tumor weight. Histochemical and immunohistochemical analysis revealed that CAPE treatment significantly reduced the number of mitotic cells and proliferating cell nuclear antigen (PCNA)-positive cells in C6 glioma. Moreover, the ability of flavonoids to scavenge free-radicals and block lipid peroxidation raises the possibility that they may act as protective factors against carcinogenesis. Furthermore, protocatechuic acid (PCA) seems to be a promising compound regarded as a candidate group for cancer preventive agents. We have isolated and investigated Hibiscus protocatechuic acid from Hibiscus sabdariffa L. Hibiscus PCA showed against oxidative damage induced by t-butyl hydroperoxide in rat primary hepatocytes, and inhibitory effect on tumor promotion in mouse skin. Finally, we review here recent progress with the analogs of natural and synthetic lead compounds in Asiatic folk medicine. Since phenolic dimmers or trimers are significantly more potent than monomer in vitro and in vivo, a large number of phenolic dimmers or trimers with linker lengths and their pharmacological properties have been investigated.


[Back to top]
Cytotoxic Molecules from Natural Sources: Tapping the Brazilian Biodiversity
I.B. Suffredini, A.D. Varella and R.N. Younes

The use of plant miscellaneous preparations as an alternative to the treatment of cancer is a reality today due to the massive marketing of natural medicines versus anticancer chemotherapy. Although this situation is controversial and has not led to any significant benefits to patients, plants may play a significant role in the treatment of cancer. Historically, natural leads have evolved to some of the outstanding medicines used nowadays against lung, breast, and ovarian cancers, and leukemia. Natural products are still some of the important sources of new anticancer drugs. The Brazilian flora is considered one of the most diverse in the world, although not many large-scale pharmacological and phytochemical studies have been conducted so far. We present the updated status and results of the research developed by Brazilian research centers on anticancer active substances derived from natural sources, mainly plants from the Brazilian Rain Forests, focusing on their potential effectiveness and difficulties.


[Back to top]
Chk1 Inhibitors for Novel Cancer Treatment
Z.-F. Tao and N.-H. Lin

Chemo- and radiotherapies that target DNA are the mainstay of cancer treatment. In response to DNA damage, cells are arrested in multiple checkpoints in the cell cycle to allow the damaged DNA to be repaired before progressing into mitosis. Normal cells are arrested in the G1 phase mediated by the p53 tumor suppressor, and p53-deficient cancer cells are arrested in the S or G2 phase. Checkpoint kinase 1 (Chk 1) is a serine / threonine protein kinase and a key mediator in the DNA damage-induced checkpoint network. When the G2 or S checkpoint is abrogated by the inhibition of Chk1, p53-deficient cancer cells undergo mitotic catastrophe and eventually apoptosis, whereas normal cells are still arrested in the G1 phase. Thus, Chk1 inhibitors can preferentially potentiate the efficacy of DNA damaging agents in cancer cells, and Chk1 is an attractive therapeutic target for cancer treatment, especially since approximately 50% of all human cancers are p53-deficient. This review discusses the rationale of Chk1 as an anticancer target, the structural basis for designing Chk1 inhibitors, and recently disclosed Chk1 inhibitors